PyramIDH

A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)

Near Add Your Location

Sorting 9 by

Center of Excellence

Memorial Sloan Kettering Cancer Center
New York, NY
  • Accepting patients

Center of Excellence

University of Chicago Medicine
Comprehensive Cancer Center
Chicago, IL
  • Accepting patients

Center of Excellence

Massachusetts General Hospital
Boston, MA
  • Accepting patients

Center of Excellence

Ohio State University Comprehensive Cancer Center
James Cancer Hospital and Solove Research Institute
Columbus, OH
  • Accepting patients

Center of Excellence

The University of Texas Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center
Dallas, TX
  • Accepting patients

Center of Excellence

MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Not yet accepting

Center of Excellence

UNC Lineberger Comprehensive Cancer Center
University of North Carolina
Chapel Hill, NC
  • Not yet accepting

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.